Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,012.54 -1.95 (-0.19%)
Streaming Delayed Price Updated: 11:44 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
These S&P500 stocks are moving in today's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
News headline image
Beyond the Giants: Gauging Emerging Large-Cap Leadership Amidst Broadening Market Dynamics
The financial markets in late 2025 are signaling a significant, albeit cautious, shift away from the concentrated leadership that has defined much of the past two years. For an extended period, market... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Eli Lilly Unusual Options Activity ↗
 
Via Benzinga
News headline image
Gapping S&P500 stocks in Friday's session ↗
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Is Johnson & Johnson Stock Outperforming the S&P 500?
Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead. 
Via Barchart.com
Topics Stocks
News headline image
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area. 
Via The Motley Fool
News headline image
Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!
As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move. 
Via Barchart.com
News headline image
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031 ↗
It's not only tech companies that can get to that market valuation. 
Via The Motley Fool
News headline image
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season. 
Via Stocktwits
Topics Economy Government
News headline image
Stock Split Watch: Is Eli Lilly Next? ↗
The stock recently reached beyond $1,000. 
Via The Motley Fool
News headline image
U.S. Stocks Extend Winning Streak as Wall Street Bets on Dovish Fed Pivot
New York, NY – November 26, 2025 – U.S. stock markets are surging, with Wall Street poised to extend a remarkable winning streak as investors enthusiastically price in aggressive interest rate cuts by... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Is AbbVie Stock Outperforming the Nasdaq?
AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
Could AI Infrastructure Spending Be the Next Gold Rush for Investors? ↗
Companies and investors see AI as a game-changing technology. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗
The weight loss drug market may approach almost $100 billion by the end of the decade. 
Via The Motley Fool
News headline image
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗
Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector. 
Via Stocktwits
News headline image
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Should You Buy the Massive Dip in Novo Nordisk Stock?
Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not. 
Via Barchart.com
News headline image
Here's Why Novo Nordisk Stock Popped Today ↗
Good news from a GLP-1 receptor agonist clinical trial hit the market today. 
Via The Motley Fool
News headline image
The Great Divide: Is the Market Offering a Dip or Signalling a Bear?
As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Is UnitedHealth Group Stock Underperforming the Nasdaq?
Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling ↗
Via MarketBeat
News headline image
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?
Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential. 
Via Barchart.com
Topics ETFs
News headline image
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000? ↗
The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap. 
Via The Motley Fool
Topics Government World Trade
News headline image
Novo Nordisk&#39;s Stock Slump Shows The GLP‑1 Trade&#39;s Side Effect: ETF Concentration Risk ↗
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience. 
Via Benzinga
Topics ETFs
News headline image
US Stock Market Navigates AI Euphoria and Rate Cut Hopes Amidst Mounting Volatility
The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint
Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement... 
Via MarketMinute
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
News headline image
Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps ↗
Eli Lilly fell while Biogen jumped. 
Via Investor's Business Daily
News headline image
Eli Lilly & Co (NYSE:LLY) Presents a Compelling Case for Growth at a Reasonable Price ↗
Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.